香港, 2024年8月24日 - (亚太商讯 via SeaPRwire.com) — 中国领先的黄金生产商–招金矿业股份有限公司（股份代号：1818，以下简称“招金矿业”或“公司”）公布截至2024年6月30日止之半年业绩。上半年，公司突出业绩导向，强化运营管理，激发经营活力，不断提升市场预判及机遇把握能力，实现营业收入约人民币46.27亿元，较去年同期上升约34.24%；净利润增长约98.82%至约人民币7.26亿元，母公司股东应占溢利增长约118.62%至约人民币5.52亿元，每股盈利增长约200%至约人民币0.12元，超预期完成上半年目标。根据中国黄金协会资料显示，2024年6月底，伦敦现货黄金定盘价为2330.90美元/盎司，较年初2074.90美元/盎司上涨12.34%，上半年均价2202.91美元/盎司，较上一年同期1931.54美元/盎司上涨14.05%。上海黄金交易所Au9999黄金上半年加权平均价格为514.12元/克，较上一年同期432.09元/克上涨18.98%。上半年，地缘政治冲突持续，全球经济复苏乏力，通胀高企，单边主义、保护主义愈演愈烈，黄金避险保值功能重新受到重视，黄金价格强势上涨，不断刷新历史新高，给公司带来市场机遇。项目支撑引领 生产经营持续向好 2024上半年，招金矿业抓住有利市场遇，围绕采掘工程、选矿管理、产品销售，科学组织生产，开展劳动竞赛，推动优产增产，共完成黄金产量13178.35千克（约42.37万盎司），其中矿产金8997.03千克（28.93万盎司），同比增长分别为7.01%。公司加快推进瑞海矿业采选工程、早子沟金矿深部开拓等重点工程，有序扩大产能规模。同时，通过探矿增储，促进可持续发展，完成地质探矿投入人民币0.42亿元，探矿新增金金属量14.31吨。上半年，公司坚定实施国际化战略，完成铁拓矿业100%股权及科马洪金矿的控股收购和现场接管。随着海外项目的持续落地，公司在西非矿业市场整体布局逐步扩大，未来将逐步形成规模、协同开发的良好态势。此外，公司始终把安全生产放在首要位置，投入安措资金人民币0.6亿元，深入开展安全生产治本攻坚行动，扎实推进提升、运输、供配电、尾矿库等重点领域专项整治，安全生产形势持续稳定。聚焦关键领域 实现增产增储增效展望2024下半年，招金矿业将强化生产组织和指标优化，围绕夏甸金矿、大尹格庄金矿、早子沟金矿等骨干矿山，挖掘扩能增产潜力。加强海外新收购矿山的运营管理，推进阿布贾金矿平稳过渡，实现稳产增产、探矿增储、扩大效益；加速推进科马洪金矿等项目建设，实现早建成、早投产。同时，公司将持续践行ESG可持续发展理念，实现安全、绿色、合规、和谐发展；强化安全防范，深化安全生产双重预防机制和隐患排查治理；健全完善合规管理体系，加大重点领域监督力度，提升公司依法合规水平；落实企业文化及民心工程建设，打造平安和谐招金。- 完 – Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月24日 - (亚太商讯 via SeaPRwire.com) — 中国领先的殡葬服务提供商--福寿园国际集团有限公司(「福寿园」或「公司」，连同其附属公司，统称「集团」；股份代号：1448.HK)公布截至2024年6月30日止六个月 (「回顾期内」) 之中期业绩。2024年上半年，中国经济整体稳定运行，长期向好。随着中国全面步入小康社会，站在了新的历史起点上，推动民生福祉达到新水准、不断增强人民群众获得感、幸福感、安全感将是中国在民生领域未来发展的主要目标。进入了新时代，人民群众对美好生活的向往从「生」延伸到「死」，提升人民群众身后事的服务质量、实现「逝有所安」已成为殡葬领域重大时代课题，并不断推动中国殡葬行业向纵深发展。回顾期内，为应对经济大环境和客户消费行为的相应变化趋势，集团从市场和产品的双重维度持续关注，在服务延展、科技引领、文化创新等领域多点发力，因「园」施策，着力满足墓园客户多元化、差异化，特别是精神层面的消费需求，持续提升产品和服务的核心竞争力，实现集团长期可持续发展。2024上半年，本集团总收益达人民币1100百万元，公司拥有人应占溢利及全面收入达人民币299百万元。董事会拟向股东派发2024年中期股息每股6.38港仙，符合本集团所承诺的派息政策，以答谢股东一直以来的支持和肯定。回顾期内，集团在公益事业、公共关系、科技创新、品牌发展方面的表现获得社会各界认可，先后获得第十届亚洲微电影艺术节「金海棠奖」、上海市优秀公关案例评选银奖、第十三届公益节「年度教育公益贡献奖」、第八届中国公益年会「年度中国公益企业」等荣誉。特别是在二零二四品牌强国论坛上，福寿园凭借30年来在品牌建设方面的创新成果，经相关部门及媒体推荐，与华为技术、国家电网、腾讯科技、阿里巴巴、抖音等共同入围「二零二四中国创新品牌500强」，福寿园品牌价值获评价人民币139.95亿元，品牌指数高达431.64分，排名第233位。截至目前，集团的业务已进入十九个省、自治区、直辖市的四十余座城市，包括上海、河南、重庆、安徽、山东、辽宁、黑龙江、福建、浙江、江西、江苏、广西、北京、贵州、内蒙古、甘肃、湖北、河北及陕西，其中包括正在运营的位于全国十七个省的主要城市、直辖市和自治区的墓园和殡仪设施。集团在全国其他重要省份、省会城市及空白区域的拓展计画仍在稳步推进中。集团将以审慎和稳健的步伐，坚守对股东负责的态度，筛选合适的目标，整合多元业务资源，以公允合理的对价收购优质资产。向生命科技服务提供者转型 墓园业务领域具有竞争力集团正在从行业领先的殡葬综合服务商转型为生命科技服务提供者，持续致力于落实「3JI」理念（记号做美，记载做厚，纪念做长）在各地、各墓园的应用。本期间内，在「3JI」理念的导引下，我们推出了墓穴产品+服务的新情绪整合产品，致力于为生命提供创新、艺术和更多维度的服务与满足。截至目前，以「3J」理念设计并成功落地的17家墓园园区，艺术美学得到了深刻的表达，从饱含人文关怀态度的设计理念到内外兼修的园区整体构造，从作为修饰性的自然景观到功能性和艺术性共存的碑体形态，对生命的敬畏和对生命美学的追求均得以彰显。此外，通过本期间「3JI」产品的多点运行，市场和客户的体验回馈令我们鼓舞和兴奋，集团相信「3JI」理念下产品和服务的应用将不断强化本集团墓园产品的核心竞争力，触动客户的需求点，助推下半年墓园业务销量的提升。上半年，在国内建筑行业整体下行的大环境下，集团设计板块的全资子公司天泉佳境专注殡葬领域的规划设计，仍保持了较为稳定的经营和发展，经营业绩及新签项目合同额较二零二三年同期均有增长。天泉佳境通过市场公开招标在本期间获得多地殡葬设施的规划设计业务，其设计实力及经营能力在国内仍保持领先地位。同时，在集团内部，天泉佳境积极践行「3JI」理念，为集团各实体公司的「3JI」规划与落地，提供了强有力的保障，进一步增强集团产品在市场上的竞争力。激发业务活力 实现殡仪业新消费需求回顾期内，集团着重在业务结构调整、客户价值创造、礼仪服务转型和科技赋能管理几个方面开展工作。通过以「新场景、新用品、新服务」为主的核心流程改造，实现现代殡仪的「新消费」需求，激发传统殡仪业务的活力，满足市场差异化、多元化的服务需求，引领行业发展。公司充分关注客户心理需求，利用智慧声光系统改造火化场景，将「冥想疗愈」服务引入告别仪式；研发安灵接运仪式及相关文创产品，提升客户对殡仪服务的体验感和获得感。同时，进一步扩大殡仪用品集中研发和集中采购范围，将「文化纸棺」、「文化灵盒」、「随行香囊」等嵌入到仪式中，确保殡仪「新文化」全覆盖。此外，集团持续推进技术含量高，如防腐和古人沐浴等高附加值服务的推广，强化自身的核心竞争力，助推殡仪服务高品质可持续发展。在人口老龄化的社会背景下，生前契约服务正吸引更多希望尽早安排好自己身后事的客户群，亦得到各级政府及长者服务机构的肯定、支援和服务采购。本期间内，累计签订生前契约11,923份合约（2023年同期：9,272份合约），较上年同期增长28.6%。销量的主要增长来自于机构、政府的解决方案的采购以及来源于制定不同目标层次的产品。自主研发环保智慧火化设备 全方位服务客户集团的环保火化机业务集研发设计、自主生产、全面配套及售后服务为一体，生产智慧环保火化设备及尾气净化处理系统。上半年，集团继续优化产品性能，持续收集客户回馈，进一步提高产品品质，降低运维成本。积极维持国内外客户，做好售前技术支持、售后维修保障工作，研发并提供了旧式JS-2火化炉更新改造服务，以使得现有客户可以分享最新的产品升级和能耗节约成果。同时，集团持续对新型拣灰炉、尾气净化系统设备进行资料统计分析验证，不断优化调整，进一步降低火化时长和燃料消耗。此外，亦在建立环保火化设备板块自身的国内外销售体系。集团亦与国内外多家潜在合作方保持密切联系，亦与多家签订了数台火化机、尾气系统和若干辅助设备的销售合作协定。随着新型城镇化进程推进后相应殡葬设施的建设、人口老龄化趋势和遗体火化率提升的加速，相信各地对环保智慧火化设备的需求将大幅增长。福寿园国际集团有限公司董事局主席兼执行董事白晓江先生表示:「福寿园持续秉承「以人为本、文化为根」的理念，正在从行业领先的殡葬综合服务商转型为生命科技服务提供者，从物理世界「福寿园」向精神世界「福寿元」发展。致力于把「记号做美，记载做厚，纪念做长」。」－完－此新闻稿由博达浩华国际财经传讯集团代福寿园国际集团有限公司发布。如有垂询，请联络：冯嘉莉 / 王佩电话：+852 3150 6788电邮：fsy@pordahavas.com Copyright 2024 亚太商讯 via SeaPRwire.com.

SINGAPORE, Aug 24, 2024 - (ACN Newswire via SeaPRwire.com) - The 2nd ASEAN Battery Technology Conference (ABTC) returned and strengthened the commitment to develop a close knitted battery development ecosystem among the Southeast Asian countries. Hosted in Singapore this year by the Singapore Battery Consortium at Singapore at the Shangri-La Rasa Sentosa between 21st and 23rd August 2024.The conference is also jointly organised by the alliance of leading battery related associations in the region - the Thailand Energy Storage Technology Association, the National Battery Research Institute, the National Center for Sustainable Transportation Technology, NanoMalaysia, and the Electric Vehicle Association of the Philippines.Dr. Pimpa Limthongkul, Co-Chairman of ABTC and President of the Thailand Energy Storage Technology Association, said, "This year, we are excited to see the expansion of what we have achieved since we last gathered together last year in Bali. Our alliance has grown from three to now six battery associations in Southeast Asia and we will continue to grow in strength. Witnessing the collaborations between the battery associations, private sector and academia is a celebration of how we are moving forward together to drive innovation for a more connected and eco-friendly future in the region.”On the second day of the conference, over 250 participants and the six leading battery associations in Southeast Asia witnessed the signing of three new Memorandums of Understanding or MoUs that will further the development of batteries in the region.From L to R: Prof. Nonglak Meethong (Professor, Khon Kaen University), Mr. Larry Poon (Business Development Manager, INV CORPORATION PTE. LTD.), Dr. Rezal Khairi Bin Ahmad (CEO, NanoMalaysia Berhad), Mr. Bryan Oh (CEO, NEU Battery Materials Pte Ltd) Mr. Freddie Kim (Managing Director, SAMSUNG SDI SOUTHEAST ASIA), Dr. Sing Yang Chiam, Technical Director Singapore Battery Consortium.Three Memorandums of UnderstandingGigafactory Malaysia (GMSB) and NEU Battery Materials (NEU) to Collaborate on Lithium Battery Recycling DevelopmentThe collaboration will focus on developing “Gigafactory” level operations and manufacturing of innovative battery technologies incorporating nanomaterials for mobility and stationary applications. This collaboration is the progression of the Memorandum of Understanding (“Memorandum”) signed in Bali, Indonesia at the 2023 ASEAN Battery and Electric Vehicle Technology Conference (ABEVTC) to promote cross-country collaboration within ASEAN on battery technology.Singapore-based, NEU, who are specialists in LFP battery recycling will ensure a steady supply of recycled battery material, like lithium carbonate and other metals are made available to GMSB’s Hydrogen-Electric-Vehicle-Battery (HEBATT) Centre for performance testing. GMSB is a subsidiary of NanoMalaysia.The testing of the recycled material is to ensure their viability and sustainability within the Malaysia battery ecosystem, which would expand to localised development of a lithium battery recycling ecosystem for the ASEAN region. NEU and GMSB will facilitate this supply and development based on spent battery material being used in an end-to-end ecosystem.This will also pave the way for the exploration of a joint-development programme for improved recycling efficiency between these two companies.Gigafactory Malaysia Sdn Bhd (GMSB) and Khon Khean University (KKU) to Collaborate on Manufacturing of Cells Developed by GMSBGMSB’s and KKU’s collaboration will leverage their joint expertise and resources, with KKU acting as the outsourced manufacturer for batteries developed by GMSB. The collaboration will also provide knowledge sharing in battery testing and certification that will lead to productivity advancements at GMSB's Hydrogen-Electric-Vehicle-Battery (HEBATT) Centre in Malaysia.This Memorandum of Understanding (MoU) is an extension of an agreement signed at the 2023 ASEAN Battery and Electric Vehicle Technology Conference (ABEVTC) in Bali, which involved key organisations from Singapore, Indonesia, Thailand, Malaysia, and the Philippines.Aligned with the ASEAN Battery Network's mission, this MoU aims to strengthen battery technology development within ASEAN.Institute of Materials Research and Engineering (IMRE), Singapore and INV Corporation to collaborate on Joint Research to Develop Hybrid Battery SeparatorsA Research Collaborative Agreement will be signed between the Institute of Materials Research and Engineering in Singapore and INV to develop the next generation hybrid battery separators, which will address the challenges of safety faced by current rechargeable batteries.This collaboration seeks to play on the strengths and IPs in solid state batteries developed in Singapore. INV is headquartered in Singapore and is the largest battery separator film manufacturer in the world. Its production plants are in Sweden and Malaysia.Samsung SDI Southeast Asia ExpansionSamsung SDI, a high-performance battery manufacturer based in South Korea, opened its Regional HQ in Southeast Asia in Singapore on 19 April 2024. Samsung SDI currently has two manufacturing sites in Southeast Asia, located in Malaysia and Vietnam. To enhance customer service, the company has established two sales offices in Vietnam (December 2023) and Singapore (April 2024).Samsung SDI Southeast Asia PTE LTD (SDISEA) also announced that it will open Samsung SDI R&D Singapore (SDIRS) on 1 September 2024, during the 2nd ASEAN Battery Technology Conference (ABTC).Under its vision of making the world greener and more sustainable through innovative technology, Samsung SDI will provide its customers in Southeast Asia with PRiMX (Prime Battery for Maximum Experience) batteries and technologies in pursuit of utmost customer satisfaction.Hosting of the ABTC is rotated among the co-organisers. In 2025, TESTA will host the ABTC in Thailand.For more information on the programme agenda, please visit our official site: https://reg.eventnook.com/event/ABTC2024/homeThe conference's anchor sponsor is Hyundai Motor Group Innovation Center Singapore (HMGICS), with the gala dinner sponsored by INV Corporation Pte Ltd.Gold sponsors include Amphenol Communications Solutions, Quantel Pte Ltd, Infineon Technologies Asia Pacific Pte Ltd, and Gotion Singapore Pte Ltd, while silver sponsors are Concord New Energy Group Limited, Kewell Technology Co.,Ltd., Metrohm Singapore Pte Ltd, TME Systems Pte Ltd.Additional sponsors include Samsung SDI Southeast Asia Pte. Ltd, Siemens Industry Software Pte Ltd, UL Standards & Engagement, and NEWARE Technology Limited. Publicity partners are the EV Association of Singapore, EV Association of Malaysia, and Turn Off Turn On Ventures.Media ContactPRecious Communicationsabtc@preciouscomms.comAbout ASEAN Battery Technology ConferenceASEAN Battery Technology Conference (ABTC) stands out as the premier battery conference in ASEAN, attracting an audience of over 250 participants. We look forward to engaging with a diverse range of participants, including cell manufacturers, pack integrators, and recycling companies. The mission of ABTC is to bring together regional battery expertise, creating unique opportunities within the global battery value chain.The primary objective of ABTC is to foster collaboration among stakeholders in the battery industry. We aim to facilitate insightful discussions covering various topics, such as advanced battery materials, prototyping, cell-to-pack technologies, and recycling strategies.In addition to these focal points, the conference will explore related aspects such as standards, interoperability, and the ongoing evolution of battery safety technology.Organisers of ABTCAbout Singapore Battery ConsortiumSingapore Battery Consortium (SBC) aims to foster strategic R&D partnerships amongst public research performers and industry players in developing and advancing battery technologies. SBC aims to develop and catalyze the local ecosystem in battery-related technologies through this platform. It is hosted at A*STAR and supported by the National Research Foundation Singapore (NRF). Over the past decade, commercial interest in battery development has been on the rise, keeping pace with demand for better battery performance and different performance characteristics for increasingly complex mobility and portable devices. To meet this demand, the Singapore Battery Consortium will bring research outcomes from our laboratories into the market by enabling researchers to understand business requirements, while giving companies access to the latest battery research and technologies to augment their product development efforts.About Thailand Energy Storage Technology Association (TESTA)TESTA or THAILAND ENERGY STORAGE TECHNOLOGY ASSOCIATION aims to help connect stakeholders, educate the public, promote understanding, and nurture technological advancements in energy storage technologies in Thailand. TESTA was officially registered on January 25, 2021, by 5 founding institutes including the National Science and Technology Development Agency (NSTDA), Khon Kaen University (KKU), King Mongkut’s University of Technology Thonburi (KMUTT), King Mongkut’s University of Technology North Bangkok (KMUT-NB), and Electric Vehicle Association of Thailand (EVAT). Over 60 members of the association include energy storage technology enthusiasts from various sectors ranging from academic, research institutes, public sectors, policymakers, and private industries.About National Center for Sustainable Transportation Technology (NCSTT)The National Center for Sustainable Transportation Technology (NCSTT), or Pusat Pengembangan Teknologi Transportasi Berkelanjutan, is from Indonesia and is a unique multidisciplinary research center focused on conducting, supporting and encouraging applied engineering and technology for transportation systems in Indonesia. NCSTT has been recognized globally as the research center which aims to foster the national transportation industry in developing national economics and welfare. NCSTT has built network linkages and research collaborations with national transportation stakeholders such as automotive, railway and aircraft industries, as well as research institutions and universities.About National Battery Research Institute (NBRI)The National Battery Research Institute (NBRI) was legally established on 17th December 2020 as The Center of Excellence Innovation of Battery and Renewable Energy Foundation, with Prof.Dr. Evvy Kartini as a Founder and Prof Alan J. Drew as Co-Founder. NBRI is Indonesia’s independent institute for electrochemical energy storage science and technology, supporting research, training, and education. NBRI aims to contribute to the overall research capacity and training environment in Indonesia in Battery Research. NBRI is a platform that brings together scientists, academicians, industry partners, the government and all stakeholders that focus on battery technology. The main goal of NBRI is to encourage and support a battery manufacturing industry using local resources, which will enable Indonesia to be independent in energy. The NBRI was supported by the UK Government’s Global Challenge Research Fund (GCRF), part of the Queen Mary University of London QR allocation.About Electric Vehicle Association of Philippines (eVAP)eVAP envisions a nation wherein the use of electric vehicles is highly promoted, encouraged and supported by its government and society to develop a transportation landscape that is one with the environment ecologically and economically. eVAP’s mission is to educate the public on environmental awareness, and the economic and ecological benefits of electric vehicles through the conduct of and/or participation in promotional activities.eVAP aims to accelerate society’s conversion from using gas-powered vehicles to electric vehicles and works with the government in the creation and implementation of legislation that will support and encourage the use of electric vehicles.About NanoMalaysiaNanoMalaysia Berhad was incorporated in 2011 as a company limited by guarantee (CLBG) under the Minister of Science, Technology and Innovation (MOSTI) to act as a business entity entrusted with nanotechnology commercialization activities. Some of its roles include commercialization of nanotechnology research and development, industrialization of nanotechnology, facilitation of investments in nanotechnology and human capital development in nanotechnology. Copyright 2024 ACN Newswire via SeaPRwire.com.

ISSYK KUL, Kyrgyzstan, Aug 24, 2024 - (ACN Newswire via SeaPRwire.com) - The Ministry of Education and Science of the Kyrgyz Republic has partnered with Singapore's Marshall Cavendish Education (MCE) to introduce key training programmes and education resources to its schools throughout the country. The partnership seeks to instill key skillsets and content knowledge to strengthen teachers and students' abilities for the 21 st century.Kyrgyzstan is set to implement significant shifts in the hopes of increasing the educational quality and to increase the number of children that attend schools. The new titles by MCE will become available to over 2000 public schools and over 1.4 million students in the country. [1]Marshall Cavendish Education's English, Mathematics and Science series from kindergarten to grades 1 till 11 will soon be available in the local languages in Kyrgyzstan with its recent partnership with Okuu Kitebi Publishing House. Alongside the new syllabus and resources, MCE is set to conduct training and mentoring programmes that aim to support the Programme for International Student Assessment (PISA) competencies of teachers and students in subjects such as Mathematics and Science. Veteran educators from Singapore will present modules to help local educators and master trainers understand key concepts such as problem-solving skills and scientific inquiry, ultimately working towards inculcating a nationwide movement to achieve an improved and sustained academic performance regionally and internationally. The partnership will also include the introduction of artificial intelligence platform Cerebry, an engine and digital platform for teachers to integrate technology within their classrooms and enhance the learning experiences of the students. Unique questions and solutions are generated on demand, for each individual student.The launch of the partnership hosted at Issyk Kul, one of the deepest lakes in the world, saw more than 200 attendees who are key stakeholders in Kyrgyzstan's education ministry. It was also attended by Deputy Prime Minister Edil Baisalov, Minister of Education and Science of Kyrgyz Republic, Dogdurkul Kendirbaeva, UNICEF Representative to the Kyrgyz Republic, Samman J. Thapa and CEO, Times Publishing Limited Siew Peng Yim."In this partnership, our key goal is to provide a strong and consistent support and motivation to our educators in Kyrgyzstan. Singapore had faced tremendous challenges in its journey to achieve success in creating a world class education ecosystem. Marshall Cavendish Education will use the lessons we had learnt from the Singapore education transformation journey to provide the necessary resources and we will also tailor-made our solutions for Kyrgyzstan to help your students to achieve academic success and more importantly to build their confidence and to enjoy learning once more," shared Mr. Siew Peng Yim, CEO, Times Publishing Limited."The books published by Marshall Cavendish Education, which over its 60-year history have established collaborations with more than 90 countries and have been translated into 17 languages, are now available to us. We believe that the books they have published contributed to the journey Singapore has had with its education. After selecting, analyzing, and studying samples from many countries, we have decided to partner with MCE. We are ready to collaborate and aim for the partnership to bring Singapore educators to share their expertise on the education system" said Ms Dogdurkul Kendirbaeva, Minister of Education and Science of Kyrgyz Republic.About Marshall Cavendish EducationMarshall Cavendish Education (MCE) is a global education solutions provider dedicated to nurturing the joy of learning and preparing students for the future. We believe the best way to do so is by simplifying learning and listening to the needs of schools, teachers, students, and parents. MCE makes world-class educational content more accessible through a seamless experience that integrates both print and digital resources. We provide holistic and end-to-end solutions customised to the school's requirements, with professional development to help educators implement the curriculum. We've worked with ministries, policymakers, educators, and parents in over 90 countries, designing education solutions in 14 languages for Pre-K to 12. MCE is the only Asia-based publisher that is an endorsement partner of Cambridge International Education.www.mceducation.comFor Media Enquiries:Shahidah HamsahName:shahidahhamsah@mceducation.com[1] https://www.unicef.org/kyrgyzstan/media/8021/file/Education%20Joint%20Sector%20Review.pdfSOURCE: Marshall Cavendish Education Pte Ltd Copyright 2024 ACN Newswire via SeaPRwire.com.

Cambridge, MA, Aug 24, 2024 - (ACN Newswire via SeaPRwire.com) - Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1."We appreciate the Ministry of Health, Labour and Welfare approval decision for our updated COVID-19 mRNA vaccine," said Stéphane Bancel, Chief Executive Officer of Moderna. "It is important that people are vaccinated with the latest updated COVID-19 vaccines that can protect against circulating strains. With COVID-19 vaccination becoming a routine inoculation similar to seasonal flu vaccines, individuals will be able to receive their updated COVID-19 vaccine alongside their flu vaccine this fall."In May 2024, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 family of Omicron subvariants for the 2024/2025 national immunization program (NIP). This guidance aligns with the recommendations from the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) on the use of a monovalent JN.1 lineage for COVID-19 vaccine antigen composition.The NIP in Japan will offer COVID-19 vaccination to individuals aged 65 and older, as well as qualifying individuals aged 60 to 64.[1] Japan has the highest proportion of older adults worldwide, with approximately 30% of its population aged 65 and above. Given that respiratory viruses are a leading disease burden in people older than 65, NIPs are crucial in reducing the burden of disease and, ultimately, future pressure on the health system. Individuals requesting COVID-19 vaccination outside of the regular program will have the option of voluntary vaccination at their own expense.In July, Moderna entered into an agreement with Mitsubishi Tanabe Pharma Corporation to support the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.Moderna Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the authorization of Moderna's updated JN.1-targeting COVID-19 vaccine by the Ministry of Health Labor and Welfare in Japan; the ability of Moderna's updated COVID-19 vaccine to induce an immune response and provide protection against circulating SARS-CoV-2 variants; and Moderna's ability to supply its COVID-19 vaccine to support Japan's COVID-19 national immunization program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.Moderna ContactsMedia :International mediaLuke Mircea-WillatsSenior Director, International CommunicationsLuke.mirceawillats@modernatx.comModerna JapanCommunications & Mediajapan-pr@modernatx.comInvestors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834Lavina.Talukdar@modernatx.com[1]Qualifying individuals include those aged 60-64 with severe cardiac, renal or respiratory impairments that significantly restrict daily activities, or those with immune deficiencies due to Human Immunodeficiency Virus (HIV), making daily life exceedingly difficult.SOURCE: Moderna, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

吉尔吉斯斯坦伊塞克湖 , 2024年8月24日 - (亚太商讯 via SeaPRwire.com) - 吉尔吉斯共和国教育与科学部与新加坡Marshall Cavendish教育公司（MCE）合作，向全国各地的学校引入关键的培训项目和教育资源。此次合作旨在培养关键技能和知识内容，以增强教师和学生在21世纪的能力。吉尔吉斯斯坦将实施重大变革，旨在提高教育质量并增加入学儿童人数。通过MCE的新教材，超过2000所公立学校和140多万名学生将受益。[1]MCE的英语、数学和科学系列教材将从幼儿园到1至11年级，随着与Okuu Kitebi出版社的合作，逐步在吉尔吉斯斯坦以当地语言推出。除了新课程和资源，MCE还将开展培训和指导项目，旨在支持教师和学生在数学和科学等科目中的国际学生评估项目（PISA）能力。来自新加坡的资深教育工作者将提供模块，帮助当地教育工作者和主培训师理解关键概念，如问题解决技能和科学探究，最终推动全国范围内实现更好和持续的地区及国际学术表现。此次合作还将引入人工智能平台Cerebry，一个供教师在课堂中整合技术、增强学生学习体验的引擎和数字平台。该平台能够根据需求，为每个学生生成独特的问题和解决方案。**在世界最深的湖泊之一伊塞克湖举办的合作启动仪式上，吸引了200多位吉尔吉斯斯坦教育部的重要利益相关者出席。吉尔吉斯斯坦副总理Edil Baisalov、教育与科学部长Dogdurkul Kendirbaeva、联合国儿童基金会（UNICEF）驻吉尔吉斯斯坦代表Samman J. Thapa，以及时报出版有限公司首席执行官Siew Peng Yim也出席了此次活动。 “在这次合作中，我们的主要目标是为吉尔吉斯斯坦的教育工作者提供强有力且持续的支持和激励。新加坡在实现创建世界一流教育生态系统的过程中，面临了巨大的挑战。Marshall Cavendish教育公司将利用我们在新加坡教育改革过程中学到的经验，提供必要的资源，并且我们还将为吉尔吉斯斯坦量身定制解决方案，帮助学生取得学业上的成功，更重要的是重建他们的自信心，并重新享受学习的乐趣，”时报出版有限公司首席执行官Siew Peng Yim说道。 “Marshall Cavendish教育公司在其60年的历史中，已与90多个国家建立合作关系，出版的书籍已被翻译成17种语言，现在这些书籍已经为我们所用。我们相信，他们出版的书籍为新加坡的教育发展作出了贡献。经过对多个国家的样本进行挑选、分析和研究后，我们决定与MCE合作。我们准备好合作，并期待这一合作能够使新加坡教育工作者分享他们在教育系统方面的专业知识，”吉尔吉斯斯坦教育与科学部长Dogdurkul Kendirbaeva说道。**关于Marshall Cavendish教育公司 Marshall Cavendish教育公司（MCE）是一家全球教育解决方案提供商，致力于培养学习的乐趣，并为学生的未来做好准备。我们相信，最好的方法是简化学习，并倾听学校、教师、学生和家长的需求。MCE通过整合印刷和数字资源的无缝体验，使世界级的教育内容更加易于获取。我们提供整体和端到端的解决方案，定制化满足学校的需求，并提供专业发展支持，帮助教育工作者实施课程。我们已与90多个国家的教育部、政策制定者、教育工作者和家长合作，设计了适用于从学前教育到12年级的教育解决方案，涵盖14种语言。MCE是唯一一家与剑桥国际教育合作的亚洲出版商。www.mceducation.com媒体垂询：Shahidah HamsahName:shahidahhamsah@mceducation.com[1]https://www.unicef.org/kyrgyzstan/media/8021/file/Education%20Joint%20Sector%20Review.pdf来源：Marshall Cavendish Education Pte Ltd Copyright 2024 亚太商讯 via SeaPRwire.com.

马萨诸塞州剑桥, 2024年8月24日 - (亚太商讯 via SeaPRwire.com) - Moderna, Inc.（纳斯达克股票代码：MRNA）今日宣布，已获得日本厚生劳动省（MHLW）批准其COVID-19 mRNA疫苗Spikevax更新配方的部分变更申请，该疫苗针对SARS-CoV-2 JN.1变异株。 “我们感谢日本厚生劳动省对我们更新后的COVID-19 mRNA疫苗作出的批准决定，”莫德纳首席执行官Stéphane Bancel表示。“确保人们接种最新更新的COVID-19疫苗，以防范现有流行的毒株，这是至关重要的。随着COVID-19疫苗接种变得像季节性流感疫苗一样成为常规接种，个人将能够在今年秋季同时接种更新后的COVID-19疫苗和流感疫苗。” 2024年5月，日本卫生部的一个专家小组建议，将COVID-19疫苗更新为针对JN.1奥密克戎子变异株家族的疫苗，用于2024/2025年度的国家免疫计划（NIP）。这一指导意见与世界卫生组织（WHO）COVID-19疫苗成分技术咨询小组（TAG-CO-VAC）关于采用单价JN.1谱系作为COVID-19疫苗抗原成分的建议保持一致。日本的国家免疫计划（NIP）将为65岁及以上的人群，以及符合条件的60至64岁人群提供COVID-19疫苗接种服务。日本是全球老龄化比例最高的国家，大约30%的人口年龄在65岁及以上。鉴于呼吸道病毒是65岁以上人群的主要疾病负担，国家免疫计划对于减轻疾病负担以及未来减轻医疗系统压力至关重要。要求在常规计划之外接种COVID-19疫苗的个人可以选择自费自愿接种。 今年7月，莫德纳与三菱田边制药株式会社达成协议，共同推广莫德纳的mRNA呼吸道疫苗组合在日本的使用，其中包括Moderna的COVID-19疫苗Spikevax。 关于ModernaModerna是mRNA医学领域的开创者。 透过推动mRNA技术的发展，Moderna正在重新构想药物的制造方式，改变我们对待和预防疾病的方式。 透过在科学、技术和健康的交汇处工作超过十年，该公司以前所未有的速度和效率开发了药物，包括最早和最有效的COVID-19疫苗之一。Moderna的mRNA平台使得能够开发用于传染性疾病、免疫肿瘤学、罕见疾病和自体免疫疾病的治疗和疫苗。 凭借着独特的文化和由Moderna的价值观和思维方式推动的全球团队，Moderna致力于透过mRNA药物为人们提供最大的可能影响。 有关Moderna的更多信息，请访问modernatx.com，并在X（前身为Twitter）、Facebook、Instagram、YouTube和LinkedIn上与我们联系。前瞻性陈述本新闻稿包含根据1995年《私人证券诉讼改革法案》修订版的定义所指的前瞻性声明，包括以下声明：日本厚生劳动省授权Moderna更新的针对JN.1的COVID-19疫苗；Moderna更新后的COVID-19疫苗诱导免疫反应并提供针对流行SARS-CoV-2变种保护的能力；以及Moderna为支持日本COVID-19国家免疫计划而供应其COVID-19疫苗的能力。本新闻稿中的前瞻性声明既不构成承诺也不构成保证，您不应过度依赖这些前瞻性声明，因为这些声明涉及已知和未知的风险、不确定性和其他因素，其中许多超出了莫德纳的控制范围，可能导致实际结果与这些前瞻性声明所表达或暗示的内容存在重大差异。這些風險、不確定性和其他因素包括但不限於，Moderna在2023年12月31日結束的財政年度的年度報告中「風險因素」一節中描述的那些風險和不確定性，該報告已向 美國證券交易委員會（SEC）提交，並在Moderna隨後向SEC提交的文件中描述，這些文件可在SEC的網站www.sec.gov上取得。 除非法律規定，Moderna不承擔更新或修訂本新聞稿中包含的任何前瞻性陳述的意圖或責任，以反映新資訊、未來發展或其他情況。 這些前瞻性陳述是基於Moderna當前的期望，並僅截至本新聞稿的日期。联络方式:媒体:International mediaLuke Mircea-WillatsSenior Director, International CommunicationsLuke.mirceawillats@modernatx.comModerna JapanCommunications & Mediajapan-pr@modernatx.com投资者:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834Lavina.Talukdar@modernatx.com[1] 符合条件的个人包括：60至64岁且患有严重心脏、肾脏或呼吸功能障碍，严重限制日常活动的个人，或因人类免疫缺陷病毒（HIV）导致免疫缺陷，致使日常生活极其困难的个人。来源：Moderna, Inc. Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月23日 - (亚太商讯 via SeaPRwire.com) — 骏码半导体材料有限公司（「骏码半导体」或「公司」，连同其附属公司统称「集团」，股份代号：8490.HK）欣然宣布截至2024年6月30日止六个月（「该期间」）之未经审核业绩。于该期间，集团录得收益约109.0百万港元（2023年上半年：约101.6百万港元）。键合线产品录得收益增加10.7%至约 58.3百万港元（2023年上半年：约52.6百万港元），而封装胶产品的收益则轻微增加2.8%至约46.8百万港元（2023年上半年：约45.6百万港元）。收益增加乃由于本集团产品的销量增加所致。在2023年全球经济受压的背景下，人工智能产业链呈现快速增长势头。踏入2024年，人工智能将进一步推动晶片运算能力、储存容量和能源效率的提升，从而促进半导体架构和先进封装的创新，有关进步有望带来新的市场增量。根据国际半导体产业协会的「年中总半导体设备预测—OEM角度」报告，预测原设备制造商 （「OEM」）于2024年的全球半导体制造设备销售额将创下新产业纪录，达到1,090亿美元，按年增加3.4%。由前端及后端市场发展带动，半导体制造设备的销售额预计将持续增长至2025年，预计销售额将达到1,280亿美元新高。聚焦半导体封装行业，中国国内制造商正逐步从传统封装向先进封装技术拓展市场占有率。人工智能、高性能计算等新需求的带动下，需求不断增长，加速了中国半导体产业的战略布局，继而促进了该拓展。尤其是在先进封装所需的材料方面，由于其技术复杂度高、制程影响大、国产率相对较低，因此受到业界的高度关注。展望未来，鉴于人工智能的快速发展，本集团将继续寻求新的业务合作，并专注于先进半导体材料的创新，以应用于电动汽车、微型LED显示、人工智能及5G通信行业。此外，集团亦会投放更多资源于5G及半导体产业的上游封装材料，预期这将成为本集团的另一增长领域。展望未来，尽管国际形势不明朗，董事会坚信集团在半导体封装材料行业的既有地位、竞争优势及灵活的业务策略，将可克服复杂环境影响，实现长期增长，为股东带来最大回报。-完-关于骏码半导体材料有限公司骏码半导体材料有限公司（「骏码半导体」）是国内半导体封装材料行业龙头企业之一，由周振基教授及周博轩博士于2006年共同创立，总部位于香港科学园区，研发及制造中心设在广东汕头，业务多点分布大湾区及华东地区。骏码半导体是一家专业从事研发、制造及销售高精密键合线、灌封材料、粘结材料等半导体封装专用物料的高新材料提供方。此新闻稿由慧悦公共关系顾问集团有限公司代表骏码半导体材料有限公司发布如有垂询，请联络慧悦公共关系顾问集团有限公司：Karena Ke电话：（852）9346-2934电邮：karena.ke@intelligentjoy.com Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月22日 - (亚太商讯 via SeaPRwire.com) —聚焦于肿瘤治疗领域的创新型生物制药公司──乐普生物科技股份有限公司(「乐普生物」或「公司」，股份代号：2157.HK) 公布2024年中期业绩。作为一家立足中国、面向全球的聚焦于肿瘤治疗领域（尤其是靶向治疗及免疫治疗）的创新型生物制药企业。乐普生物致力于通过先进的ADC技术开发平台开发创新型ADC，并旨在开发出更优化、更创新的药物，更好地填补癌症患者的临床需求缺口。公司致力于通过内部研发与战略合作相结合的方式持续开发市场差异化管线，加强自主生产能力。目前，乐普生物已战略性布局了多个肿瘤产品管线。就临床阶段候选药物而言，公司的产品中有一种临床 / 商业化阶段候选药物；七种临床阶段候选药物（包括一种透过合营企业共同开发的药物）；及三种临床阶段的候选药物的联合疗法。其中一种候选药物已获得两种靶向适应症的上市批准，其他适应症临床试验正在进行中。商业化稳定再超亿元 核心产品销售较去年同期增加一倍于报告期内，公司在推进产品管线及业务营运方面均取得重大进展，其中核心产品普佑恒®（普特利单抗注射液）的销售收入达人民币94.8百万元，较2023年同期增加一倍，为公司收益人民币133.3百万元之主要贡献。ADC管线及其与癌症免疫的联合疗法亦取得多项重大进展。而于创新平台研发的候选药物临床前获得良好数据。于2023年4月，普特利单抗已成功获纳入用于治疗黑色素瘤和MSI-H/dMMR实体瘤的2023年CSCO及CSGO指南，表明临床KOL的高度认可。公司积极发展与各种业务渠道合作伙伴的合作关系。截至2024年6月30日，已在26个省份的采购平台上完成了招标程序，并已通过各种销售渠道覆盖约78个城市，将进一步扩大销售网络。ADC管线及其与癌症免疫的联合疗法取得重大进展公司的ADC候选药物包括MRG003、MRG002、MRG004A、MRG001、MRG006A及CMG901。ADC管线及其与癌症免疫的联合疗法在上半年取得了重大进展。- MRG003：目前已完成NPC IIb期注册性临床研究的患者入组，预期将于2024年下半年于中国申报NDA。于2024年7月，公司已就MRG003用于治疗R/M NPC于美国获FDA授予BTD。MRG003与普佑恒®（普特利单抗注射液）的联合疗法：公司正在进行MRG003与普特利单抗联合治疗实体瘤的I/II期试验，并已完成I期试验。公司已观察到良好的初步数据，该等数据已在2024年ASCO年会上以口头汇报形式呈现。公司目前正在进行II期试验并已观察到良好的数据，该等数据计划于2024年ESMO亚洲年会上呈现。- MRG002：已于中国完成HER2高表达BC肝转移II期关键临床试验的患者入组，并观察到良好数据，预期将于2024年CSCO上呈现。同时，公司正在进行HER2阳性BC的III期临床试验。MRG002与普佑恒®（普特利单抗注射液）的联合疗法：公司正在进行MRG002与普特利单抗联合治疗HER2表达实体瘤患者的II期试验，并已于UC患者中观察到良好的初步数据，预期将在2024年ESMO大会上呈现。- MRG004A：公司目前正在美国及中国进行实体瘤I期临床研究，并已在PC、TNBC及CC中观察到良好数据。实体瘤的相关初步I期数据已在2024年ASCO年会上以口头汇报形式呈现。于2024年3月，MRG004A已获FDA授予FTD，用于治疗经过过往批准的疗法治疗的复发性或难治性PC。公司正在扩展I期临床试验PC患者亚组，以进一步探索MRG004A用于PC的更多潜力。- MRG006A：公司已于2024年AACR年会上公布良好的临床前数据。于临床前研究中，MRG006A在多种CDX模型及HCC PDX模型中展现出强大的剂量依赖性的对肿瘤的生长抑制作用。同时，MRG006A亦在探索性毒理学研究中表现出良好的耐受性。根据良好的临床前表现，公司已于中国获得IND批准，且目前正在进行I期临床研究，而该研究已于2024年8月实现首例患者入组。临床前：布局创新平台和创新靶点公司持续致力于建立和开发新型技术平台。除临床验证的vc-MMAE平台外，亦已为ADC候选药物开发多个创新的链接体－ 有效载荷平台，包括Hi-TOPi平台及其他早期阶段的平台。于报告期内，公司的创新ADC平台及T细胞衔接器平台TOPAbody取得了重大进展。依托该等创新平台，已开发出两款ADC候选药物，分别为具有全球首创新药潜力的MRG006A及具有全球同类最优潜力的MRG007，以及新一代T细胞激动性抗体CTM012。公司已观察到良好的临床前研究数据，并已于中国获得MRG006A的IND批准。同时，亦正在高效推进MRG007及CTM012进入临床研究阶段。MRG006A及TOPAbody平台的临床前数据已于2024年4月在AACR年会上呈现。未来展望展望2024年下半年，公司将继续加快两款主要ADC产品MRG003及MRG002的开发，迈向下一个里程碑。公司预期将于2024年下半年于中国就MRG003申报NDA，并将努力加快审批进程。公司亦将探索MRG004A及MRG006A等其他创新候选药物的更多潜在临床价值。同时，不断探索管线内的联合疗法的潜在疗效，以为更多患者带来临床效益。就创新分子而言，致力加强建设创新平台，并全力推进创新分子CTM012及MRG007进入临床研究阶段。2024年，公司将致力于深化市场营销及商业化，并积极扩大在中国的市场足迹及产品知名度。这包括促进普佑恒®（普特利单抗注射液）的市场准入，继续加快各级市场渗透，以进一步扩大市场份额。同时，公司将寻求通过各种方式提升品牌形象及市场对公司产品的认识。在国际方面，公司将加大在全球市场的拓展力度。由于ADC平台已获跨国公司认可，预期公司的其他ADC产品将有更大的业务发展机会。日后，公司将坚持不懈地扩大国际网络，并通过多项策略探索新的业务开发合作机会，以促进我们的发展及成功。 Copyright 2024 亚太商讯 via SeaPRwire.com.